The Solitaire™ X portfolio is designed to give you greater confidence during interventional stroke procedures with:
The overlapping stent design allows the device to expand in larger vessels and compress in smaller vessels during deployment and retrieval3 as well as:
Our Solitaire X Revascularization Device — designed with an optimized delivery system — produces lower delivery force7 for improved procedural efficiency and smooth navigation through even the most complicated anatomy.
The distinctive, evenly-spaced platinum markers let you visualize the optimal working length and stent behavior for real-time procedural feedback, ensuring accurate alignment, optimal revascularization, and clot capture success.2
The 6x40 length device simplifies placement with proximal ophthalmic alignment, providing complete visualization and coverage from M2 to ICA.4,6
Our Solitaire portfolio is backed by published data with 11+ trials and case studies worldwide, proving it reduces stroke-related disability in patients suffering a large vessel acute ischemic stroke following IV t-PA.9-19
Our AIS portfolio offers comprehensive, compatible solutions that give your patients a better chance to walk away from AIS.
See the Neurovascular Product Catalog for more.
Solitaire Economic Value Video
See how stroke treatment with the Solitaire device provides economic value.
The Solitaire X portfolio is designed to give you greater confidence during interventional stroke procedures.
Brianne was 24 when she had her first stroke. Watch her story.
1. The Solitaire X Revascularization Device is indicated for use to restore blood flow in the neurovasculature by removing thrombus for the treatment of acute ischemic stroke to reduce disability in patients with a persistent, proximal anterior circulation, large vessel occlusion, and smaller core infarcts who have first received intravenous tissue plasminogen activator (IV t-PA ). Endovascular therapy with the device should be started within 6 hours of symptom onset.
2. The Solitaire X Revascularization Device is indicated to restore blood flow by removing thrombus from a large intracranial vessel in patients experiencing ischemic stroke within 8 hours of symptom onset. Patients who are ineligible for IV t-PA or who fail IV t-PA therapy are candidates for treatment.
3. The Solitaire X Revascularization Device is indicated for use to restore blood flow in the neurovasculature by removing thrombus for the treatment of acute ischemic stroke to reduce disability in patients with a persistent, proximal anterior circulation, large vessel occlusion of the internal carotid artery (ICA) or middle cerebral artery (MCA)-M1 segments with smaller core infarcts (<70 cc by CTA or MRA, <25 cc by MR-DWI). Endovascular therapy with the device should start within 6-16 hours of time last seen well in patients who are ineligible for intravenous tissue plasminogen activator (IV t-PA) or who fail IV t-PA therapy.
Cello is a trademark of and is manufactured by Fuji Systems Corporation.
TR-NV16168 Rev A
TR-NV12692 Rev A
TR-NV13807 Rev A
TR-NV15666A Rev A
TR-NV12180 Rev A
Umansky, F. et al. Microsurgical anatomy of the proximal segments of the middle cerebral artery
Compared to Solitaire™ Platinum
TR-NV12554 Rev A
Goyal M, Demchuk AM, Menon BK, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. N. Engl. J. Med. Mar 12 2015;372(11):1019-1030.
Mueller-Kronast NH, Zaidat OO, Froehler MT, et al. Systematic Evaluation of Patients Treated With Neurothrombectomy Devices for Acute Ischemic Stroke: Primary Results of the STRATIS Registry. Stroke. 2017;48(10):2760-2768.
Saver JL, Goyal M, Bonafe A, et al. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. N. Engl. J. Med. Jun 11 2015;372(24):2285-2295.
TN Nguyen & Al. Balloon Guide Catheter Improves Revascularization and Clinical Outcomes With the Solitaire Device. Stroke. 2014;45:141-145.
Serge Bracard, Xavier Ducrocq, et al. Mechanical thrombectomy after intravenous alteplase versus alteplase alone after stroke (THRACE): a randomized controlled trial. Lancet Neurol. 2016; 15: 1138–47.
Jovin TG, Chamorro A, Cobo E, et al. Thrombectomy within 8 hours after symptom onset in ischemic stroke. N. Engl. J. Med. Jun 11 2015;372(24):2296-2306.
Berkhemer OA, Fransen PS, Beumer D, et al. A randomized trial of intraarterial treatment for acute ischemic stroke. N. Engl. J. Med. Jan 1 2015;372(1):11-20.
Pereira VM, Gralla J, Davalos A, et al. Prospective, multicenter, single-arm study of mechanical thrombectomy using Solitaire Flow Restoration in acute ischemic stroke. Stroke. Oct 2013;44(10):2802-2807.
Campbell BC, Mitchell PJ, Kleinig TJ, et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N. Engl. J. Med. Mar 12 2015;372(11):1009-1018.
Goyal M, Menon BK, van Zwam WH, et al. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomized trials. Lancet. Apr 23 2016;387(10029):1723-1731.
Campbell BC, Hill MD, Rubiera M, et al. Safety and Efficacy of Solitaire Stent Thrombectomy: Individual Patient Data Meta-Analysis of Randomized Trials. Stroke; a journal of cerebral circulation. 2016;47(3):798-806.
71042-001 Rev B
STRATIS, SWIFT PRIME, ESCAPE, Nasa Registry, THRACE, MR CLEAN, STAR, EXTEND IA, HERMES, SEER, REVASCAT, DEFUSE 3, Note: The Solitaire™ X Revascularization Device was not evaluated in these studies.
Phenom 21 Catheter